Greater empathy in MDMA users

Carlyle and colleagues frame their study around MDMA's well-documented acute prosocial effects — increases in compassion, trust, generosity and empathy — and its capacity to attenuate responses to social threat and social exclusion. Earlier experimental work has shown that, acutely, MDMA preferentially enhances emotional empathy (the tendency to feel others' emotions) over cognitive empathy (the ability to infer others' mental states, sometimes called 'theory of mind'), and these effects are thought to involve serotonergic mechanisms and hormones such as oxytocin. At the same time, preclinical and imaging studies have raised concerns that heavy, chronic MDMA use may reduce 5-HT transporter markers, which could plausibly impair social functioning over the long term; however, much of that imaging literature has sampled exceptionally heavy users, and the causal direction of findings is uncertain. The current study set out to characterise whether repeated, predominantly low-level recreational MDMA use is associated with altered social functioning, focusing on empathy and sensitivity to social exclusion (social pain). Carlyle and colleagues targeted mild but regular MDMA users to better approximate doses likely to be used in therapeutic contexts and compared them with two control groups: poly-drug users who do not use MDMA, and alcohol-only users. They hypothesised that chronic MDMA use might impair empathy and increase sensitivity to social pain consistent with serotonergic dysfunction, although they also note alternative possibilities framed by recent evidence suggesting preserved or even enhanced empathy with repeated MDMA exposure.

An independent groups (cross-sectional) design compared three groups: MDMA poly-drug users, non-MDMA poly-drug users, and alcohol-only users. Seventy-five individuals (25 male, 50 female) aged 18–43 (mean = 21.41, SD = 3.27) were recruited from the community by advertisement and snowball sampling; participants were blind to the study's MDMA focus. Inclusion criteria for the MDMA group required MDMA use at least once a month for the past 10 months and/or more than 10 lifetime uses. The non-MDMA poly-drug group required equivalent frequency/quantity criteria for illicit substances excluding MDMA, and alcohol-only users reported no illicit drug use. All participants were asked to abstain from drugs and alcohol for 24 hours prior to testing. Exclusion criteria included autism spectrum disorder, neurological disorders, and severe mental illness; one participant was subsequently excluded from empathy analyses due to a later-disclosed Asperger's diagnosis. The extracted text does not clearly report the final analysed sample size in every section, but later degrees of freedom indicate analyses were typically conducted on 67 participants. Participants completed a combination of questionnaires and computerised tasks in a laboratory session lasting about one hour. Trait empathy was measured using the Interpersonal Reactivity Index (IRI), which yields subscales for emotional empathy (empathic concern, personal distress) and cognitive empathy (perspective taking, fantasy). State and task-based empathy were assessed with the Multifaceted Empathy Test (MET), a computerised task presenting 40 emotionally charged photographs: four blocks required emotion identification (cognitive empathy) and four asked participants to rate how much they empathised on a nine-point scale (emotional empathy). Social exclusion was modelled with the Cyberball Game, a computerized ball-toss paradigm with counterbalanced inclusion and exclusion conditions; affective responses after each block were measured with the Post-Ostracism Cyberball Questionnaire (POCQ). Drug and alcohol history was obtained by structured interview covering lifetime and recent (two-week) use; MDMA users provided additional questions about MDMA. Statistical analysis was performed in SPSS v23. Assumptions of normality and homogeneity were checked; group effects on IRI and MET outcomes were tested with one-way ANOVA, and Cyberball outcomes were analysed with mixed measures ANOVA (group × inclusion status). Non-normal variables were transformed or analysed with non-parametric tests (Kruskal-Wallis) as appropriate. Exploratory Pearson correlations examined relationships between drug-use indices and empathy measures. Post hoc comparisons were corrected using Holm–Bonferroni adjustments.

Sample and matching: The three groups were reported as matched for age, gender, years in education and history of substance-use problems; the MDMA group showed a non-significant trend toward a higher prevalence of historical mental health treatment. The extracted text indicates minor reports of past MDMA use in the non-MDMA groups but little recent MDMA use outside the MDMA group. Subjective empathy (IRI): A significant group effect emerged for empathic concern (emotional empathy subscale) (F(2,64) = 6.42, p = .003, η² = .17). Post hoc Holm–Bonferroni corrected tests showed MDMA users scored higher than non-MDMA poly-drug users (t(42) = 3.54, p = .004, η² = .23), while the difference between MDMA users and alcohol-only users did not reach significance (t(46) = 2.19, p = .066, η² = .09). No group differences were found on the personal distress subscale (F(2,64) = 1.74, p = .185, η² = .05). For cognitive empathy subscales, there was a trend for the fantasy scale (F(2,64) = 3.06, p = .054, η² = .09) but no group differences in perspective taking (F(2,64) = 1.06, p = .352, η² = .03). MET (computerised task): On task-based cognitive empathy (correct emotion identification), there was a significant group effect (F(2,64) = 3.69, p = .031, η² = .10). MDMA users performed better than non-MDMA poly-drug users (t(42) = 2.85, p = .028, η² = .16), but did not differ from alcohol-only users (t(46) = 1.39, p = .342, η² = .04); non-MDMA and alcohol-only groups did not differ. There were no group differences on the MET emotional empathy ratings (F(2,64) = 0.71, p = .496, η² = .02). Social pain (Cyberball/POCQ): Across all participants, exclusion (versus inclusion) produced the expected effects: decreases in positive affect, self-esteem, control, and perceived percentage of ball throws, and increases in negative affect. However, there were no significant main effects of group nor group × inclusion status interactions on these indices. Some POCQ subscales were highly skewed and analysed as change scores; these too showed no group differences. Exploratory correlations and additional analyses: Thirteen participants reported MDMA use within two weeks of testing; grams used in that period did not correlate significantly with MET emotional empathy (r = 0.44, n = 11, p = .177). Within the MDMA group, ecstasy use (days per month) was not significantly correlated with IRI empathic concern (r = -0.20, n = 24, p = .343) or MET cognitive empathy (r = -0.19, n = 24, p = .371). Empathic concern on the IRI correlated with MET emotional empathy (r = 0.42, n = 67, p < .001), whereas perspective taking did not correlate with MET cognitive empathy (r = -0.11, n = 67, p = .398). Analyses excluding any occasional MDMA users in the control groups produced similar patterns but effects weakened after correction for multiple comparisons. Overall, the main consistent findings were higher self-reported empathic concern in the MDMA group versus non-MDMA poly-drug users, and better task-based cognitive empathy in MDMA users versus non-MDMA poly-drug users.

Carlyle and colleagues interpret their findings as indicating that mild, repeated recreational MDMA use is not associated with impaired interpersonal functioning in this sample; rather, MDMA users showed elevated self-reported emotional empathy (empathic concern) compared with non-MDMA poly-drug users, and improved cognitive empathy on a computerised task, replicating aspects of prior work. No differences were found between groups in responses to experimentally induced social exclusion, suggesting that sensitivity to social pain was not altered by the level of MDMA use studied. The authors consider several explanations: enhanced empathy among MDMA users might reflect long-term consequences of repeated acute empathogenic experiences (autobiographical reinforcement), pre-existing differences that predispose some individuals to use MDMA, or differential sensitivity of measures (the IRI assesses trait-like, introspective aspects of empathy, whereas the MET assesses more immediate, state-like empathic responses). They note that their findings align with prior reports that light users can show enhanced cognitive empathy while heavier use has been associated with poorer performance in some studies. Key limitations acknowledged by the study team include reliance on self-reported drug-use histories rather than objective assays (e.g. hair or urine analysis), the cross-sectional design that cannot determine causality or rule out pre-existing group differences, modest sample size that may reduce power for some comparisons, and imperfect matching between drug-using groups on patterns of non-MDMA drug use. The authors also observe a non-significant trend toward higher rates of past mental health treatment in the MDMA group, which could confound results but did not reach statistical significance. In terms of implications, the investigators suggest that, at the low levels of repeated use sampled, MDMA does not appear to produce long-term deficits in empathy or increase sensitivity to social pain and may be associated with enhanced prosocial traits. They caution that these data cannot establish whether empathy differences precede or follow MDMA use and recommend prospective and objective-measure studies. The authors also flag potential clinical relevance, noting that preserved or enhanced empathy could be favourable for therapeutic applications of MDMA (for example in PTSD, autism spectrum disorder, or alcohol use disorder), while emphasising the need for further research to evaluate benefits and risks across different dosing regimens and populations.